| pubmed-article:7590662 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7590662 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:7590662 | lifeskim:mentions | umls-concept:C1513157 | lld:lifeskim |
| pubmed-article:7590662 | lifeskim:mentions | umls-concept:C0292863 | lld:lifeskim |
| pubmed-article:7590662 | lifeskim:mentions | umls-concept:C0887824 | lld:lifeskim |
| pubmed-article:7590662 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:7590662 | pubmed:dateCreated | 1995-12-14 | lld:pubmed |
| pubmed-article:7590662 | pubmed:abstractText | Our aim was to isolate potentially important differentially expressed gene products from paired human hepatocellular carcinoma (HCC) and normal liver samples using the differential messenger RNA (mRNA) display technique. Total RNA samples were reverse transcribed with anchoring oligonucleotide primers and then amplified by the polymerase chain reaction (PCR) with additional upstream random primers. Differentially expressed complementary DNA (cDNA) products were subsequently used as probes in Northern blot analysis. One such cDNA product, present in tumor but absent in normal displays, showed identity with the adhesion molecule integrin alpha 6. In Northern blot of 16 HCC pairs, the approximately 5.5 kb signal of integrin alpha 6 mRNA was overexpressed in seven tumors, with a weak signal in the normal livers. For those patients with versus without integrin alpha 6 mRNA overexpression: (1) grade III (or IV) histology was noted in seven of seven versus three of nine tumors, respectively (P = .03); (2) tumor recurrence or death (at mean follow-up of 18 months) was noted in six of seven versus three of eight patients, respectively (P = .17). Similar results were obtained using semiquantitative PCR co-amplification with glyceraldehyde 3-phosphate dehydrogenase as a control; approximately 50% of the tumors had stronger integrin alpha 6 bands than their paired normals. Both A and B variants of integrin alpha 6 mRNA were detectable in the tumor and normal liver samples.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7590662 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7590662 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7590662 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7590662 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7590662 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7590662 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7590662 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7590662 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7590662 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7590662 | pubmed:issn | 0270-9139 | lld:pubmed |
| pubmed-article:7590662 | pubmed:author | pubmed-author:TakenakaKK | lld:pubmed |
| pubmed-article:7590662 | pubmed:author | pubmed-author:MoriMM | lld:pubmed |
| pubmed-article:7590662 | pubmed:author | pubmed-author:BarnardG FGF | lld:pubmed |
| pubmed-article:7590662 | pubmed:author | pubmed-author:SugimachiKK | lld:pubmed |
| pubmed-article:7590662 | pubmed:author | pubmed-author:MatsumataTT | lld:pubmed |
| pubmed-article:7590662 | pubmed:author | pubmed-author:BegumN ANA | lld:pubmed |
| pubmed-article:7590662 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7590662 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:7590662 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7590662 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7590662 | pubmed:pagination | 1447-55 | lld:pubmed |
| pubmed-article:7590662 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:meshHeading | pubmed-meshheading:7590662-... | lld:pubmed |
| pubmed-article:7590662 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7590662 | pubmed:articleTitle | Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. | lld:pubmed |
| pubmed-article:7590662 | pubmed:affiliation | Department of Medicine, University of Massachusetts Medical Center, Worcester 01655-0310, USA. | lld:pubmed |
| pubmed-article:7590662 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7590662 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7590662 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7590662 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7590662 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7590662 | lld:pubmed |
